<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215120</url>
  </required_header>
  <id_info>
    <org_study_id>DESI.19.001.01</org_study_id>
    <nct_id>NCT04215120</nct_id>
  </id_info>
  <brief_title>Desidustat in the Treatment of Anemia in CKD on Dialysis Patients</brief_title>
  <acronym>DREAM-D</acronym>
  <official_title>A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the&#xD;
      efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of&#xD;
      anemia in patients with CKD on dialysis. (DREAM-D)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Hb levels from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>No. of subjects with Hb response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin target range</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to achieve target range Hb level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Chronic Kidney Disease Stage 5 on Dialysis</condition>
  <arm_group>
    <arm_group_label>Desidustat oral tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desidustat Oral Tablet</intervention_name>
    <description>Desidustat tablet</description>
    <arm_group_label>Desidustat oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <description>Epoetin Injection</description>
    <arm_group_label>Epoetin Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Ability to understand and give informed consent for participation. 2. Hemoglobin values&#xD;
        during the screening period must be 8-11 g/dL (both inclusive).&#xD;
&#xD;
        3.&#xD;
&#xD;
          1. Patients will be considered not treated with erythropoietin analogue (Epoetin and&#xD;
             Darbepoeitin) if they have not received erythropoietin analogue for at least 4 weeks&#xD;
             and Mircera® for at least 8 weeks prior to screening visit. OR&#xD;
&#xD;
          2. Patients who are on ESA therapy must be on stable dose for 4 weeks prior to enrollment&#xD;
             (≤30% of dose change).&#xD;
&#xD;
             4. Patients on hemodialysis (≥2 times in a week) for at least 12 weeks prior to&#xD;
             screening visit and have access consisting of an arteriovenous fistula, AV graft, or&#xD;
             catheter (permanent/temporary).&#xD;
&#xD;
             5. Patients with no planned change in dialysis modality and with no planned renal&#xD;
             transplant during study period.&#xD;
&#xD;
             6. Left ventricular ejection fraction ≥40% by echocardiogram prior to randomization.&#xD;
&#xD;
             7. No iron, folate or Vitamin B12 deficiency.&#xD;
&#xD;
             8. Females of childbearing potential, must agree to use one of the approved&#xD;
             contraception methods, from screening until completion of the follow-up visit.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               1. Red blood cell transfusion within 8 weeks prior to participating in the study.&#xD;
&#xD;
               2. History of previous or concurrent cancer.&#xD;
&#xD;
               3. Serologic status reflecting active hepatitis B or C infection or Human&#xD;
                  immunodeficiency virus (HIV) infection.&#xD;
&#xD;
               4. Active infection at initiation of study.&#xD;
&#xD;
               5. History of renal transplant.&#xD;
&#xD;
               6. Uncontrolled hypertension (defined as SBP &gt;180 mmHg or DBP &gt;100 mmHg) at&#xD;
                  screening visit (before dialysis).&#xD;
&#xD;
               7. Patient on high rhEPO dose at screening visit. [High dose defined as an epoetin&#xD;
                  dose of ≥450 IU/kg/week intravenous or ≥ 300 IU/kg/week subcutaneous or&#xD;
                  darbepoetin dose of ≥1.5 µg/kg/week subcutaneous].&#xD;
&#xD;
               8. Major surgery within 90 days of the first day of study drug dosing, and minor&#xD;
                  surgery within 30 days of the first day of study drug dosing.&#xD;
&#xD;
               9. Unable to swallow tablets or disease significantly affecting gastrointestinal&#xD;
                  function and/or inhibiting small intestine absorption such as; malabsorption&#xD;
                  syndrome, resection of the small bowel or poorly controlled inflammatory bowel&#xD;
                  disease affecting the small intestine.&#xD;
&#xD;
              10. History of uncontrolled autoimmune hemolytic anemia, idiopathic thrombocytopenic&#xD;
                  purpura (ITP) or thalassemia.&#xD;
&#xD;
              11. Presence or a history of bleeding disorders or clinical conditions (e.g.&#xD;
                  gastrointestinal [GI] bleeding or constitutional disorders) that may increase&#xD;
                  risk of life-threatening bleeding.&#xD;
&#xD;
              12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
              13. History of allergic reactions attributed to compounds of similar chemical or&#xD;
                  biologic composition to Desidustat or Epoetin alfa or to any&#xD;
                  erythropoieisis-stimulating agent.&#xD;
&#xD;
              14. Pregnant and breastfeeding women.&#xD;
&#xD;
              15. Current life-threatening illness, medical condition or organ system dysfunction&#xD;
                  which, in the Investigator's opinion, could compromise the patient's safety.&#xD;
&#xD;
              16. Other laboratory abnormalities that, in the opinion of the investigator, would&#xD;
                  compromise the patient's safety or interfere with data interpretation.&#xD;
&#xD;
              17. Presence of other clinically significant systemic disorders or diseases (e.g.,&#xD;
                  respiratory, gastrointestinal, endocrine, immunological, dermatological,&#xD;
                  neurological, psychiatric disease or any other body system involvement) which, in&#xD;
                  the Investigator's opinion, could compromise the patient's safety.&#xD;
&#xD;
              18. History of significant alcoholism or drug abuse within the past 1 year. History&#xD;
                  or presence of significant smoking (more than 10 cigarettes per day) or&#xD;
                  consumption of tobacco/nicotine products (more than 10 times per day).&#xD;
&#xD;
              19. History of difficulty with donating blood.&#xD;
&#xD;
              20. History or presence of any clinically significant electrocardiogram (ECG)&#xD;
                  abnormalities during screening.&#xD;
&#xD;
              21. Participants who have participated in any drug research study other than the&#xD;
                  present trial within past 3 months.&#xD;
&#xD;
              22. Participants who have donated one unit (350 ml) of blood in the past 3 months or&#xD;
                  history of whole blood transfusion in last 120 days prior to entry in the study.&#xD;
&#xD;
              23. Existing clinically active chronic inflammatory disease (RA, Celiac disease, UC,&#xD;
                  Crohns disease)&#xD;
&#xD;
              24. In case of DM patients, HbA1c &gt;9%.&#xD;
&#xD;
              25. Female volunteers with following criteria will not be recruited:&#xD;
&#xD;
                    -  History of pregnancy or lactation in the past 3 months&#xD;
&#xD;
                    -  Fertile female volunteers not protected against pregnancy by adequate long-&#xD;
                       term anti-fertility measures&#xD;
&#xD;
                    -  History of less than 1 year of menopause and not using adequate long-term&#xD;
                       anti-fertility measures&#xD;
&#xD;
                    -  Positive urine pregnancy test at Visit 2&#xD;
&#xD;
                    -  Positive serum β-hCG level at the screening visit&#xD;
&#xD;
              26. Currently active clinically significant cardiovascular disease such as&#xD;
                  uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac&#xD;
                  disease as defined by the New York Heart Association Functional Classification or&#xD;
                  history of myocardial infarction prior to first dose with study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Deven Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cadila Healthcare Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karnavati Hospital Pvt.Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalby Hospital,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DHS Multispecialty Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chopda Medicare &amp; Research Centre Pvt. Ltd</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aditya Birla Memorial Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eternal Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Star Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

